

# Ciro Gallo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6194786/publications.pdf>

Version: 2024-02-01

164  
papers

12,810  
citations

31976

53  
h-index

24258

110  
g-index

168  
all docs

168  
docs citations

168  
times ranked

12780  
citing authors

#	ARTICLE	IF	CITATIONS
1	A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients. <i>Hepatology</i> , 1998, 28, 751-755.	7.3	1,271
2	Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 1999, 91, 66-72.	6.3	901
3	Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2003, 95, 362-372.	6.3	768
4	Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. <i>Hepatology</i> , 2000, 31, 840-845.	7.3	546
5	Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderly Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 6865-6872.	1.6	452
6	Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data. <i>Journal of Clinical Oncology</i> , 2012, 30, 1692-1698.	1.6	422
7	c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.. <i>Journal of Clinical Oncology</i> , 1996, 14, 2702-2708.	1.6	380
8	Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 910-915.	1.6	361
9	Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 396-405.	10.7	327
10	Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant <i>Acinetobacter baumannii</i> : A Multicenter, Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2013, 57, 349-358.	5.8	322
11	Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 1645-1651.	1.6	279
12	Gemcitabine Plus Vinorelbine Compared With Cisplatin Plus Vinorelbine or Cisplatin Plus Gemcitabine for Advanced Non-Small-Cell Lung Cancer: A Phase III Trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2003, 21, 3025-3034.	1.6	232
13	First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The TORCH Randomized Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3002-3011.	1.6	229
14	Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. <i>Lancet</i> , The, 1998, 352, 17-20.	13.7	210
15	Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy. <i>Cancer</i> , 2005, 104, 1362-1371.	4.1	207
16	Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. <i>Lancet Oncology</i> , The, 2005, 6, 669-677.	10.7	197
17	Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 3628-3635.	1.6	182
18	Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 1836-1843.	1.6	166

#	ARTICLE	IF	CITATIONS
19	Risk of warfarin during pregnancy with mechanical valve prostheses. <i>Obstetrics and Gynecology</i> , 2002, 99, 35-40.	2.4	163
20	The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. <i>Cancer</i> , 1995, 76, 1772-1778.	4.1	162
21	A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. <i>British Journal of Cancer</i> , 2004, 91, 1996-2004.	6.4	158
22	Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 2635-2642.	1.6	149
23	Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 561-568.	10.7	141
24	Activity and toxicity of gemcitabine and gemcitabine+vinorelbine in advanced non-small-cell lung cancer elderly patients. <i>Lung Cancer</i> , 2001, 31, 277-284.	2.0	123
25	Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial. <i>Gut</i> , 2001, 48, 28-33.	12.1	117
26	Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2004, 90, 2288-2296.	6.4	111
27	Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With Once Every Week Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 1377-1382.	1.6	110
28	Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. <i>Lancet Oncology</i> , The, 2022, 23, 382-392.	10.7	107
29	The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy. <i>Annals of Oncology</i> , 2016, 27, 2224-2229.	1.2	103
30	Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. <i>British Journal of Cancer</i> , 1991, 63, 799-803.	6.4	101
31	Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. <i>European Journal of Cancer</i> , 1997, 33, 392-397.	2.8	101
32	Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCOVID-19 prospective trial. <i>Journal of Translational Medicine</i> , 2020, 18, 405.	4.4	98
33	Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 1254-1262.	10.7	95
34	Pulse wave velocity is associated with muscle mass decline: Health ABC study. <i>Age</i> , 2012, 34, 469-478.	3.0	92
35	Prognostic Value of Circulating Melanoma Cells Detected by Reverse Transcriptase-Polymerase Chain Reaction. <i>Journal of Clinical Oncology</i> , 2003, 21, 767-773.	1.6	91
36	Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEMcitabine-COxib in NSCLC (GECO) study. <i>Lancet Oncology</i> , The, 2007, 8, 500-512.	10.7	89

#	ARTICLE	IF	CITATIONS
37	Prognosis of CKD Patients Receiving Outpatient Nephrology Care in Italy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2421-2428.	4.5	88
38	Health effects associated with the disposal of solid waste in landfills and incinerators in populations living in surrounding areas: a systematic review. <i>International Journal of Public Health</i> , 2013, 58, 725-735.	2.3	79
39	Cisplatin Plus Gemcitabine or Vinorelbine for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The MILES-2P Studies. <i>Journal of Clinical Oncology</i> , 2007, 25, 4663-4669.	1.6	77
40	Antiproteinuric Response to Dual Blockade of the Renin-Angiotensin System in Primary Glomerulonephritis: Meta-analysis and Metaregression. <i>American Journal of Kidney Diseases</i> , 2008, 52, 475-485.	1.9	76
41	The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology care. <i>Kidney International</i> , 2012, 82, 482-488.	5.2	75
42	A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 229-236.	4.4	72
43	Hepatic Resection and Percutaneous Ethanol Injection as Treatments of Small Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2003, 36, 63-67.	2.2	71
44	Endocrine Effects of Adjuvant Letrozole Compared With Tamoxifen in Hormone-Responsive Postmenopausal Patients With Early Breast Cancer: The HOBOE Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 3192-3197.	1.6	71
45	Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual data of nine randomised trials. <i>European Journal of Cancer</i> , 2010, 46, 735-743.	2.8	71
46	Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3347-3353.	1.6	66
47	Phase II Study of Cisplatin and Vinorelbine as First-Line Chemotherapy in Patients With Carcinoma of the Uterine Cervix. <i>Journal of Clinical Oncology</i> , 1999, 17, 756-756.	1.6	65
48	Informed versus randomised consent to clinical trials. <i>Lancet</i> , The, 1995, 346, 1060-1064.	13.7	61
49	Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. <i>British Journal of Cancer</i> , 2000, 83, 707-714.	6.4	60
50	High cardiovascular risk in patients with Type 2 diabetic nephropathy: the predictive role of albuminuria and glomerular filtration rate. The NID-2 Prospective Cohort Study. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2269-2274.	0.7	60
51	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 474-485.	10.7	59
52	Prognostic value of circulating tumor cells™ reduction in patients with extensive small-cell lung cancer. <i>Lung Cancer</i> , 2014, 85, 314-319.	2.0	56
53	Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. <i>Annals of Oncology</i> , 2015, 26, 675-682.	1.2	56
54	Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5506-5506.	1.6	55



#	ARTICLE	IF	CITATIONS
73	Hormonal Treatment of Human Hepatocellular Carcinoma. <i>Annals of the New York Academy of Sciences</i> , 2006, 1089, 252-261.	3.8	33
74	Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. <i>Annals of Oncology</i> , 1996, 7, 821-826.	1.2	32
75	An International, Multicenter, Randomized Phase III Study of First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Versus First-Line Cisplatin/Gemcitabine Followed by Second-Line Erlotinib in Advanced Non-Small-Cell Lung Cancer: Treatment Rationale and Protocol Dynamics of the TORCH Trial. <i>Clinical Lung Cancer</i> , 2008, 9, 235-238.	2.6	32
76	Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials. <i>Lung Cancer</i> , 2012, 76, 457-464.	2.0	32
77	Quality of life in elderly cancer patients. <i>Annals of Oncology</i> , 2001, 12, S49-S52.	1.2	31
78	First-Line Chemotherapy With Fluorouracil and Folinic Acid for Advanced Colorectal Cancer in Elderly Patients. <i>Journal of Clinical Gastroenterology</i> , 2003, 36, 228-233.	2.2	31
79	Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2009, 63, 251-258.	2.0	31
80	Methodological aspects of lung cancer clinical trials in the era of targeted agents. <i>Lung Cancer</i> , 2010, 67, 127-135.	2.0	30
81	Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant <i>Acinetobacter baumannii</i> infections. <i>Clinical Microbiology and Infection</i> , 2016, 22, 984-989.	6.0	30
82	CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). <i>British Journal of Cancer</i> , 1995, 71, 1283-1287.	6.4	28
83	A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. <i>British Journal of Cancer</i> , 2007, 96, 1639-1643.	6.4	28
84	Epidemiological study on behavioural and emotional problems in developmental age: prevalence in a sample of Italian children, based on parent and teacher reports. <i>Italian Journal of Pediatrics</i> , 2014, 40, 19.	2.6	28
85	Supportive care in patients with advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2003, 89, 1013-1021.	6.4	27
86	Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. <i>British Journal of Cancer</i> , 2006, 94, 1233-1236.	6.4	27
87	Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole. <i>Journal of Clinical Oncology</i> , 1998, 16, 1414-1419.	1.6	25
88	Statistical design in phase II clinical trials and its application in breast cancer. <i>Lancet Oncology</i> , The, 2003, 4, 305-311.	10.7	25
89	Rationale and Design of MILES-3 and MILES-4 Studies: Two Randomized Phase 3 Trials Comparing Single-Agent Chemotherapy Versus Cisplatin-Based Doublets in Elderly Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 166-170.	2.6	25
90	Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1086-1097.	1.1	25

#	ARTICLE	IF	CITATIONS
91	Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the Naples adjuvant (GUN) study. <i>British Journal of Cancer</i> , 1990, 62, 643-646.	6.4	23
92	Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: Safety data from the multicentre phase 3 randomised ELDA trial. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 171-180.	4.4	23
93	Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. <i>Lung Cancer</i> , 2010, 67, 86-92.	2.0	23
94	Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1830-1844.	1.1	23
95	Endocrine treatment of hepatocellular carcinoma. Any evidence of benefit?. <i>European Journal of Cancer</i> , 1998, 34, 25-32.	2.8	22
96	Outcome of Patients With a Performance Status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES). <i>Journal of Clinical Oncology</i> , 2004, 22, 5018-5020.	1.6	22
97	Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBEO study. <i>Annals of Oncology</i> , 2012, 23, 2027-2033.	1.2	22
98	Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon- $\alpha$ in advanced malignant melanoma. <i>Journal of Translational Medicine</i> , 2013, 11, 38.	4.4	21
99	Carboplatin plus vinorelbine plus G-CSF in elderly patients with extensive-stage small-cell lung cancer: a poorly tolerated regimen. Results of a multicentre phase II study. <i>Lung Cancer</i> , 2002, 36, 327-332.	2.0	20
100	Survival after Locoregional Treatments for Hepatocellular Carcinoma: A Cohort Study in Real-World Patients. <i>Scientific World Journal</i> , The, 2012, 2012, 1-7.	2.1	19
101	The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2019, 153, 535-540.	1.4	19
102	Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2006, 6, 196.	2.6	18
103	Off-Label Prescription of Antineoplastic Drugs: An Italian Prospective, Observational, Multicenter Survey. <i>Tumori</i> , 2009, 95, 647-651.	1.1	18
104	A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization) Tj ETQqO 02gBT /Overlock 10	2.6	18
105	Immunological Phenotype Analysis of Patients with Fanconi's Anaemia and Their Family Members. <i>Acta Haematologica</i> , 1998, 100, 39-43.	1.4	16
106	Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2118475.	5.9	16
107	Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC. <i>Oncotarget</i> , 2016, 7, 72654-72661.	1.8	15
108	Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study. <i>British Journal of Cancer</i> , 2001, 84, 38-41.	6.4	14

#	ARTICLE	IF	CITATIONS
109	Re: Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. Journal of the National Cancer Institute, 2008, 100, 1557-1557.	6.3	14
110	Development and validation of a patient-reported outcome tool to assess cancer-related financial toxicity in Italy: a protocol. BMJ Open, 2019, 9, e031485.	1.9	14
111	Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial. BMC Cancer, 2011, 11, 75.	2.6	13
112	A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCID-19 trial): Statistical analysis plan. Contemporary Clinical Trials Communications, 2020, 20, 100665.	1.1	13
113	The MITO8 phase III international multicenter randomized study testing the effect on survival of prolonging platinum-free interval (PFI) in patients with ovarian cancer (OC) recurring between 6 and 12 months after previous platinum-based chemotherapy: A collaboration of MITO, MANGO, AGO, BGO, ENGOT, and GCIG.. Journal of Clinical Oncology, 2016, 34, 5505-5505.	1.6	13
114	Prognostic Value of CD40 in Adult Soft Tissue Sarcomas. Clinical Cancer Research, 2004, 10, 2824-2831.	7.0	12
115	A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system. Supportive Care in Cancer, 2021, 29, 3219-3233.	2.2	12
116	Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system. BMJ Open, 2021, 11, e049128.	1.9	12
117	Steroid hormone receptor levels and adjuvant tamoxifen in early breast cancer. Breast Cancer Research and Treatment, 1990, 16, 111-117.	2.5	11
118	Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study. British Journal of Cancer, 2005, 93, 896-904.	6.4	11
119	First-Line Chemotherapy for HER-2â€“Negative Metastatic Breast Cancer Patients Who Received Anthracyclines as Adjuvant Treatment. Oncologist, 2007, 12, 1288-1298.	3.7	11
120	Selecting high-risk early breast cancer patients: What to add to the number of metastatic nodes?. European Journal of Cancer, 1996, 32, 41-46.	2.8	10
121	Chemotherapy-induced neutropenia: a useful predictor of treatment efficacy?. Nature Clinical Practice Oncology, 2006, 3, 114-115.	4.3	10
122	A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients. Lung Cancer, 2017, 108, 15-21.	2.0	10
123	Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials. BMC Cancer, 2021, 21, 549.	2.6	10
124	Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials. Gynecologic Oncology, 2019, 154, 83-88.	1.4	9
125	TOCID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol. Contemporary Clinical Trials, 2020, 98, 106165.	1.8	9
126	MITO-11: A randomized multicenter phase II trial testing the addition of pazopanib to weekly paclitaxel in platinum-resistant or -refractory advanced ovarian cancer (AOC).. Journal of Clinical Oncology, 2014, 32, 5503-5503.	1.6	9



#	ARTICLE	IF	CITATIONS
127	The First Breast Cancer Screening Program in Southern Italy: Preliminary Results from Three Municipalities of the Naples Province. <i>Tumori</i> , 1995, 81, 7-12.	1.1	8
128	Survey of Modalities of Toxicity Assessment and Reporting in Noncomparative Prospective Studies of Chemotherapy in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 52-57.	1.6	8
129	A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 1021-1027.	2.3	8
130	Treatment withdrawal in relapsing/remitting multiple sclerosis: a retrospective cohort study. <i>European Journal of Neurology</i> , 2016, 23, 489-493.	3.3	8
131	Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer. <i>Annals of Oncology</i> , 2018, 29, 1189-1194.	1.2	8
132	Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial. <i>European Journal of Cancer</i> , 2021, 148, 422-429.	2.8	8
133	Survey of Modalities of Toxicity Assessment and Reporting in Noncomparative Prospective Studies of Chemotherapy in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 52-57.	1.6	7
134	Assessing Financial Toxicity in Patients With Cancer: Moving Away From a One-Size-Fits-All Approach. <i>Journal of Oncology Practice</i> , 2019, 15, 460-461.	2.5	7
135	Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. <i>Oncotarget</i> , 2017, 8, 57528-57536.	1.8	7
136	Predictivity of clinical, laboratory and imaging findings in diagnostic definition of palpable thyroid nodules. A multicenter prospective study. <i>Endocrine</i> , 2018, 61, 43-50.	2.3	6
137	Etiological, clinical and laboratory data of post-transfusion hepatitis: A retrospective study of 379 cases from 53 Italian hospitals. <i>Infection</i> , 1987, 15, 111-114.	4.7	5
138	Phase II study of intensive CEV (Carboplatin, Epirubicin and VP-16) Plus G-CSF (granulocyte-colony) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2424-2426.	2.8	5
139	Tamoxifen in hepatocellular carcinoma. <i>Lancet</i> , The, 1998, 352, 820.	13.7	5
140	Phase I-II Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly Patients with Performance Status 0-2: The G-Step Trial. <i>Journal of Thoracic Oncology</i> , 2012, 7, 233-242.	1.1	5
141	Generalizability of SPRINT-CKD cohort to CKD patients referred to renal clinics. <i>Journal of Nephrology</i> , 2019, 32, 429-435.	2.0	5
142	Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials. <i>Lung Cancer</i> , 2019, 133, 62-68.	2.0	5
143	Chemotherapy in the Elderly. <i>New England Journal of Medicine</i> , 2002, 346, 622-623.	27.0	4
144	Clinical trial design in oncology. <i>Lancet Oncology</i> , The, 2004, 5, 759-763.	10.7	4

#	ARTICLE	IF	CITATIONS
145	Cost of Insurance Policies for Investigator-Initiated Cancer Clinical Trials in Italy. <i>Tumori</i> , 2005, 91, 373-379.	1.1	4
146	Insurance for independent cancer trials. <i>Annals of Oncology</i> , 2004, 15, 1722-1723.	1.2	3
147	Time Spent for Activation of Non-Profit Studies in Oncology in Italy. <i>PLoS ONE</i> , 2010, 5, e11864.	2.5	3
148	Carboplatin plus paclitaxel scheduling for advanced ovarian cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2014, 15, e250-e251.	10.7	3
149	Cisplatin in addition to single-agent first-line chemotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC): efficacy results of a joint analysis of the multicentre, randomized phase 3 MILES-3 and MILES-4 studies. <i>Annals of Oncology</i> , 2017, 28, vi2.	1.2	3
150	Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E), or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer: The FATA-GIM3 trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 515-515.	1.6	3
151	Clinical trial design in oncology: statistical power. <i>Lancet Oncology</i> , The, 2004, 5, 760-1.	10.7	3
152	Endocrine Factors in the Outcome of Systemic Adjuvant Therapy of Early Breast Cancer. <i>Annals of the New York Academy of Sciences</i> , 1993, 698, 330-338.	3.8	2
153	Reply to P.E. Lønning et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e103-e104.	1.6	2
154	The opportunity of patient-journey studies for academic clinical research in oncology. <i>BMJ Open</i> , 2021, 11, e052871.	1.9	2
155	Immunosuppressive Therapy of HBsAg-Positive Chronic Active Hepatitis in Childhood. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1988, 7, 17-21.	1.8	1
156	Prognostic Significance of Circulating Immune Complexes in a Long-Term Follow-Up of Breast Cancer Patients. <i>Oncology</i> , 1988, 45, 337-343.	1.9	1
157	Risk of warfarin during pregnancy with mechanical valve prostheses. <i>Obstetrics and Gynecology</i> , 2002, 100, 1041.	2.4	1
158	A prognostic index for patients within the intermediate stage of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 592-598.	1.6	1
159	Prospective validation of the International Warfarin Pharmacogenetics Consortium algorithm in high-risk elderly people (VIALE study). <i>Pharmacogenomics Journal</i> , 2020, 20, 451-461.	2.0	1
160	Re: Visualizing Length of Survival in Time-to-Event Studies: A Complement to Kaplan-Meier Plots. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1188-1188.	6.3	0
161	Reply to V. Lorusso et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 289-290.	1.6	0
162	Reply to P. Baldo et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 2826-2826.	1.6	0

#	ARTICLE	IF	CITATIONS
163	PROGNOSTIC-SIGNIFICANCE OF MULTIFOCALITY IN PRIMARY BREAST-CANCER. <i>Oncology Reports</i> , 1994, 1, 1045-8.	2.6	0
164	MITO (Multicentre Italian Trials in Ovarian cancer): CERV 2 trialâ€”A randomized phase II study of carboplatin and paclitaxel +/- cetuximab, in advanced and/or recurrent cervical cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5520-5520.	1.6	0